Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Perrigo Company plc

Cost of Revenue: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, understanding cost structures is crucial. This chart provides a fascinating comparison between Intra-Cellular Therapies, Inc. and Perrigo Company plc from 2014 to 2023.

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. has shown a dynamic trajectory in its cost of revenue. Starting with a modest $140,000 in 2015, the company experienced a significant surge, peaking at approximately $93 million in 2016. This represents a staggering increase of over 66,000% in just one year. By 2023, the cost of revenue stabilized around $34 million, indicating a more mature phase in its business operations.

Perrigo Company plc

In contrast, Perrigo Company plc maintained a relatively stable cost of revenue, averaging around $3 billion annually. This consistency underscores Perrigo's established market presence and operational efficiency. Despite minor fluctuations, Perrigo's cost structure reflects its robust business model.

This comparison highlights the diverse strategies and growth phases of these two pharmaceutical giants, offering valuable insights into their financial health and market strategies.